- Home
- REBN vs NCNA Comparison
REBN vs NCNA Comparison
Compare REBN & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- NCNA
- Stock Information
- Founded
- REBN 2015
- NCNA 1997
- Country
- REBN United States
- NCNA United Kingdom
- Employees
- REBN N/A
- NCNA N/A
- Industry
- REBN Restaurants
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- NCNA Health Care
- Exchange
- REBN Nasdaq
- NCNA Nasdaq
- Market Cap
- REBN 9.4M
- NCNA 7.6M
- IPO Year
- REBN 2022
- NCNA 2017
- Fundamental
- Price
- REBN $1.97
- NCNA $3.82
- Analyst Decision
- REBN
- NCNA
- Analyst Count
- REBN 0
- NCNA 0
- Target Price
- REBN N/A
- NCNA N/A
- AVG Volume (30 Days)
- REBN 51.5K
- NCNA 76.4K
- Earning Date
- REBN 11-19-2025
- NCNA 11-13-2025
- Dividend Yield
- REBN N/A
- NCNA N/A
- EPS Growth
- REBN N/A
- NCNA N/A
- EPS
- REBN N/A
- NCNA N/A
- Revenue
- REBN $6,663,303.00
- NCNA N/A
- Revenue This Year
- REBN $335.98
- NCNA N/A
- Revenue Next Year
- REBN N/A
- NCNA N/A
- P/E Ratio
- REBN N/A
- NCNA N/A
- Revenue Growth
- REBN 21.09
- NCNA N/A
- 52 Week Low
- REBN $1.05
- NCNA $2.78
- 52 Week High
- REBN $8.30
- NCNA $330.00
- Technical
- Relative Strength Index (RSI)
- REBN 56.00
- NCNA 50.98
- Support Level
- REBN $1.59
- NCNA $3.10
- Resistance Level
- REBN $1.94
- NCNA $3.88
- Average True Range (ATR)
- REBN 0.16
- NCNA 0.28
- MACD
- REBN 0.05
- NCNA 0.07
- Stochastic Oscillator
- REBN 81.82
- NCNA 81.19
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.